A Prospective Cohort Study on the Impact of SGLT2 Inhibitors on the 12‑Month Recurrence Risk of Atrial Fibrillation After Catheter Ablation
Abstract
Background Catheter ablation (CA) effectively maintains sinus rhythm in atrial fibrillation (AF) patients, but its postoperative recurrence rate remains high (20–40%), necessitating safe and effective adjuvant therapies. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have cardioprotective effects, yet high-quality evidence on their value and impact on AF recurrence post-CA is insufficient. Methods This single-center observational study prospectively enrolled AF patients undergoing first-time cardiac radiofrequency CA (Jan 2020-Dec 2023). Patients were split into the SGLT2i group (106 cases, 10mg daily dapagliflozin/empagliflozin) and the control group (324 cases). 1:3 propensity score matching (PSM, 13 variables including gender, age, BMI) balanced baselines. Kaplan-Meier analysis compared 12-month AF-free survival; univariate and multivariate Cox models analyzed SGLT2i-AF recurrence association. Results A total of 430 patients were enrolled, with an overall 12-month AF recurrence rate of 21.63% (93/430). Kaplan-Meier analysis demonstrated higher 12-month AF-free survival in the SGLT2i group (total cohort Log-rank P = 0.019; PSM cohort Log-rank P = 0.016). Multivariate Cox analysis confirmed SGLT2i use was independently associated with a reduced risk of AF recurrence (total cohort: HR = 0.459, 95% CI = 0.228–0.926, P = 0.030; PSM cohort: HR = 0.458, 95% CI = 0.223–0.939, P = 0.033). Conclusion Postoperative SGLT2i use correlates with lower 12-month AF recurrence risk in…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 430 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.